Acadia Pharmaceuticals' schizophrenia drug fails in late-stage study
11/03/2024 20:13
March 11 (Reuters) - Acadia Pharmaceuticals ACAD.O said on Monday its experimental drug to treat negative symptoms of schizophrenia failed to meet the main goal in a late-stage study. (Reporting by Mariam Sunny in Bengaluru) ((Mariam.ESunny@thomsonreuters.com;))
Recent news on Acadia Pharmaceuticals
See all newsU.S. STOCKS ON THE MOVE-FactSet, Moderna, Goldman Sachs
U.S. STOCKS ON THE MOVE-Biogen, Incyte, Quantum Cyber
U.S. STOCKS ON THE MOVE-Fortrea, Nuvation Bio, Acadia Pharmaceuticals
Acadia Pharma jumps after EU panel reverses opinion on neurological disorder drug
Brief: Daybu® (Trofinetide) Recommended For Approval In The European Union By CHMP